Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ashesh Gandhi, Paul Balmer & Laura J. York. (2016) Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®). Postgraduate Medicine 128:6, pages 548-556.
Read now
Read now
Annaliesa S. Anderson, Li Hao, Qin Jiang, Shannon L. Harris, Thomas R. Jones, John L. Perez, Laura York, Joseph Eiden & Kathrin U. Jansen. (2013) Potential impact of the bivalent rLP2086 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease. Human Vaccines & Immunotherapeutics 9:3, pages 471-479.
Read now
Read now
Lin H Chen, David R Hill & Annelies Wilder-Smith. (2011) Vaccination of travelers: how far have we come and where are we going?. Expert Review of Vaccines 10:11, pages 1609-1620.
Read now
Read now
Eleanor Barnes & Andrew J Pollard. (2011) Vaccines in clinical trials: infectious disease. Expert Review of Vaccines 10:5, pages 555-557.
Read now
Read now
Articles from other publishers (18)
Viktoriia Yu. Savitskaya, Nina G. Dolinnaya, Vadim V. Strekalovskikh, Elizaveta S. Peskovatskova, Viktoriia G. Snyga, Vadim S. Trefilov, Mayya V. Monakhova & Elena A. Kubareva. (2023) Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years: Vaccine Efficacy Prognosis. Medical Sciences 11:4, pages 76.
Crossref
Crossref
Federica Bianchi, Daniele Veggi, Laura Santini, Francesca Buricchi, Erika Bartolini, Paola Lo Surdo, Manuele Martinelli, Oretta Finco, Vega Masignani, Matthew J. Bottomley, Domenico Maione & Roberta Cozzi. (2019) Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6. The FASEB Journal 33:11, pages 12099-12111.
Crossref
Crossref
T. Tenenbaum, W. Hellenbrand & H. Schroten. (2019) Impfstoffe gegen Meningokokken für das KindesalterVaccines against meningococci for children. Monatsschrift Kinderheilkunde 167:3, pages 196-205.
Crossref
Crossref
Matt Shirley & Muhamed-Kheir Taha. (2018) MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years. Drugs 78:2, pages 257-268.
Crossref
Crossref
Carol J. Baker. (2016) Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations. Journal of Adolescent Health 59:2, pages S29-S37.
Crossref
Crossref
Matt Shirley & Sohita Dhillon. (2015) Bivalent rLP2086 Vaccine (Trumenba®): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10–25 Years. BioDrugs 29:5, pages 353-361.
Crossref
Crossref
Eduardo Rojas, Johanna Hoyos, Neil J. Oldfield, Philip Lee, Mike Flint, C. Hal Jones, Dlawer A. A. Ala’Aldeen, Kathrin U. Jansen & Annaliesa S. Anderson. (2015) Optimization of Molecular Approaches to Genogroup Neisseria meningitidis Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B Vaccines. PLOS ONE 10:7, pages e0132140.
Crossref
Crossref
Sophie M Andrews & Andrew J Pollard. (2014) A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. The Lancet Infectious Diseases 14:5, pages 426-434.
Crossref
Crossref
Susan K. Hoiseth, Ellen Murphy, Lubomira Andrew, Ulrich Vogel, Matthias Frosch, Wiebke Hellenbrand, Raquel Abad, Julio A. Vazquez, Ray Borrow, Jamie Findlow, Muhamed-Kheir Taha, Ala-Eddine Deghmane, Dominique A. Caugant, Paula Kriz, Martin Musilek, Leonard W. Mayer, Xin Wang, Jessica R. MacNeil, Laura York, Charles Y. Tan, Kathrin U. Jansen & Annaliesa S. Anderson. (2013) A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H–Binding Proteins and Implications for Vaccine Coverage in Different Age Groups. Pediatric Infectious Disease Journal 32:10, pages 1096-1101.
Crossref
Crossref
Michael D. Nissen, Helen S. Marshall, Peter C. Richmond, Qin Jiang, Shannon L. Harris, Thomas R. Jones, Kathrin U. Jansen & John L. Perez. (2013) A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents. Pediatric Infectious Disease Journal 32:4, pages 364-371.
Crossref
Crossref
Helen S. Marshall, Peter C. Richmond, Michael D. Nissen, Ann Wouters, James Baber, Qin Jiang, Annaliesa S. Anderson, Thomas R. Jones, Shannon L. Harris, Kathrin U. Jansen & John L. Perez. (2013) A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 31:12, pages 1569-1575.
Crossref
Crossref
Enrico MalitoAgnese FaleriPaola Lo SurdoDaniele VeggiGiulietta MaruggiEva GrassiElena CartocciIsabella BertoldiAlessia GenoveseLaura SantiniGiacomo RomagnoliErica BorgogniSébastien BrierCarla Lo Passo, Maria DominaFlora CastellinoFranco Felici, Stijn van der Veen, Steven Johnson, Susan M. Lea, Christoph M. Tang, Mariagrazia PizzaSilvana SavinoNathalie NoraisRino RappuoliMatthew J. BottomleyVega Masignani. (2013) Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proceedings of the National Academy of Sciences 110:9, pages 3304-3309.
Crossref
Crossref
Helen S. Marshall, Peter C. Richmond, Michael D. Nissen, Qin Jiang, Annaliesa S. Anderson, Kathrin U. Jansen, Graham Reynolds, John B. Ziegler, Shannon L. Harris, Thomas R. Jones & John L. Perez. (2012) Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18–36 Months. Pediatric Infectious Disease Journal 31:10, pages 1061-1068.
Crossref
Crossref
P.C. Richmond, M.D. Nissen, H.S. Marshall, S.B. Lambert, D. Roberton, W.C. Gruber, T.R. Jones & A. Arora. (2012) A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 30:43, pages 6163-6174.
Crossref
Crossref
Jordan S. Orange, Mark Ballow, E. Richard Stiehm, Zuhair K. Ballas, Javier Chinen, Maite De La Morena, Dinakantha Kumararatne, Terry O. Harville, Paul Hesterberg, Majed Koleilat, Sean McGhee, Elena E. Perez, Jason Raasch, Rebecca Scherzer, Harry Schroeder, Christine Seroogy, Aarnoud Huissoon, Ricardo U. Sorensen & Rohit Katial. (2012) Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. Journal of Allergy and Clinical Immunology 130:3, pages S1-S24.
Crossref
Crossref
Davide Serruto, Matthew J. Bottomley, Sanjay Ram, Marzia M. Giuliani & Rino Rappuoli. (2012) The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens. Vaccine 30, pages B87-B97.
Crossref
Crossref
Matthew J. Bottomley, Davide Serruto, Marco Aurélio Palazzi Sáfadi & Keith P. Klugman. (2012) Future challenges in the elimination of bacterial meningitis. Vaccine 30, pages B78-B86.
Crossref
Crossref
Mariagrazia Pizza, Lisa DeTora & James Wassil. (2012) Advances in meningococcal vaccines. Clinical Practice 9:1, pages 101-117.
Crossref
Crossref